Search

Your search keyword '"Stach, B."' showing total 209 results
Start Over Author "Stach, B."
209 results on '"Stach, B."'

3. Guide for follow-up of patients with SARS-CoV-2 pneumonia. Management proposals developed by the French-language Respiratory Medicine Society

Author

Andréjak, Claire, Blanc, F.-X., Costes, F., Crestani, B., Debieuvre, D., Perez, T., Philippe, B., Plantier, L., Schlemmer, F., Sesé, L., Stach, B., Uzunhan, Y., Zanetti, C., Zysman, M., Raherison, C., Maitre, B., Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 (AGIR ), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de Pneumologie et Centre de Compétence des Maladies Pulmonaires Rares [AP-HP Hôpital Bichat, Paris], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Emile Muller [Mulhouse] (CH E.Muller Mulhouse), Groupe Hospitalier de Territoire Haute Alsace (GHTHA), Service d'explorations fonctionnelles respiratoires [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier René Dubos [Pontoise], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Henri Mondor, Hopital Avicennes, Université Paris 13 (UP13), Cabinet Medicale St Michel, Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cabinet médical, CHU Bordeaux [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and ROSSI, Sabine

Subjects
body regions, Plethysmography, CT scan, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Follow-up, fungi, skin and connective tissue diseases, Fibrosis, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, respiratory tract diseases, COVID
Abstract

International audience; The French-language Respiratory Medicine Society (SPLF) proposes a guide for the follow-up of patients who have presented with SARS-CoV-2 pneumonia. The proposals are based on known data from previous epidemics, on acute lesions observed in SARS-CoV-2 patients and on expert opinion. This guide proposes a follow-up based on three categories of patients: (1) patients managed outside hospital for possible or proven SARS-CoV-2 infection, referred by their physician for persistent dyspnoea; (2) patients hospitalized for SARS-CoV-2 pneumonia in a medical unit; (3) patients hospitalized for SARS-CoV-2 pneumonia in an intensive care unit. The subsequent follow-up will have to be adapted to the initial assessment. This guide emphasises the possibility of others causes of dyspnoea (cardiac, thromboembolic, hyperventilation syndrome...). These proposals may evolve over time as more knowledge becomes available.

Published
2020

5. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe dʼOncologie de langue française (GOLF)

Author

Couraud, S., Cortot, A. B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G. R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2013
Full Text
View/download PDF

21. Évaluation par auto-questionnaire de qualité de vie VQ11 de l’impact d’un traitement bronchodilatateur dans la BPCO en pratique pneumologique

Author

Dayen, C., primary, Perez, T., additional, Carre, O., additional, Bethembos, S., additional, Benoit, N., additional, Catto, M., additional, Maetz, E., additional, Proisy, D., additional, Stach, B., additional, Verkindre, C., additional, Dury, S., additional, Bentaleb, A., additional, Pallenchier, S., additional, Just, N., additional, Fournier, C., additional, Khamis, W., additional, Dewolf, M., additional, Dumont, P., additional, Douadi, Y., additional, Andrejak, C., additional, Jounieaux, V., additional, and Ninot, G., additional

Published
2016
Full Text
View/download PDF

23. FADS1 FADS2 gene cluster, PUFA intake and blood lipids in children

Author

Standl, M., Lattka, E., Stach, B., Koletzko, S., Bauer, C.P., von Berg, A., Berdel, D., Krämer, U., Schaaf, B., Roder, S., Herbarth, O., Buyken, A., Drogies, T., Thiery, J., Koletzko, B., Heinrich, J., GINIplus Study Group (Heinrich, J., Wichmann, H.-E., Popescu, M., Schoetzau, A., Franke, K., Mosetter, M., Sausenthaler, S., Schindler, J., Zirngibl, A., Thaqi, A., Zutavern, A., Laubereau, B.), LISAplus Study Group (Wichmann, H.-E., Bolte, G., Belcredi, P., Jacob, B., Höhnke, A., Laubereau, B., and Zutavern, A.)

Subjects
Fatty Acid Desaturases, Male, Epidemiology, lcsh:Medicine, Blood lipids, Cardiovascular, Biochemistry, Pediatrics, Cohort Studies, chemistry.chemical_compound, High-density lipoprotein, Delta-5 Fatty Acid Desaturase, 0302 clinical medicine, Germany, Surveys and Questionnaires, Pediatric Cardiology, Prospective Studies, lcsh:Science, Pediatric Epidemiology, Child, Genetics, chemistry.chemical_classification, 2. Zero hunger, 0303 health sciences, Multidisciplinary, Fatty Acids, Lipids, 3. Good health, Genetic Epidemiology, Multigene Family, 030220 oncology & carcinogenesis, Fatty Acids, Unsaturated, Medicine, Female, lipids (amino acids, peptides, and proteins), Polyunsaturated fatty acid, Research Article, medicine.medical_specialty, Genotype, FADS1, FADS2, 030209 endocrinology & metabolism, Biology, Polymorphism, Single Nucleotide, Environmental Epidemiology, 03 medical and health sciences, Internal medicine, medicine, Humans, Alleles, Genetic Association Studies, Triglycerides, 030304 developmental biology, Evolutionary Biology, Triglyceride, Population Biology, Cholesterol, lcsh:R, Cholesterol, HDL, Computational Biology, Cholesterol, LDL, Diet, Minor allele frequency, Endocrinology, chemistry, Genetic Polymorphism, lcsh:Q, Population Genetics, 030217 neurology & neurosurgery
Abstract

BACKGROUND: Elevated cholesterol levels in children can be a risk factor for cardiovascular diseases in later life. In adults, it has been shown that blood lipid levels are strongly influenced by polymorphisms in the fatty acid desaturase (FADS) gene cluster in addition to nutritional and other exogenous and endogenous determinants. Our aim was to investigate whether lipid levels are determined by the FADS genotype already in children and whether this association interacts with dietary intake of n-3 fatty acids. METHODS: The analysis was based on data of 2006 children from two German prospective birth cohort studies. Total cholesterol, HDL, LDL and triglycerides were measured at 10 years of age. Six single nucleotide polymorphisms (SNPs) of the FADS gene cluster were genotyped. Dietary n-3 fatty acid intake was assessed by food frequency questionnaire. Linear regression modeling was used to assess the association between lipid levels, n-3 fatty acid intake and FADS genotype. RESULTS: Individuals carrying the homozygous minor allele had lower levels of total cholesterol [means ratio (MR) ranging from 0.96 (p = 0.0093) to 0.98 (p = 0.2949), depending on SNPs] and LDL [MR between 0.94 (p = 0.0179) and 0.97 (p = 0.2963)] compared to homozygous major allele carriers. Carriers of the heterozygous allele showed lower HDL levels [β between -0.04 (p = 0.0074) to -0.01 (p = 0.3318)] and higher triglyceride levels [MR ranging from 1.06 (p = 0.0065) to 1.07 (p = 0.0028)] compared to homozygous major allele carriers. A higher n-3 PUFA intake was associated with higher concentrations of total cholesterol, LDL, HDL and lower triglyceride levels, but these associations did not interact with the FADS1 FADS2 genotype. CONCLUSION: Total cholesterol, HDL, LDL and triglyceride concentrations may be influenced by the FADS1 FADS2 genotype already in 10 year old children. Genetically determined blood lipid levels during childhood might differentially predispose individuals to the development of cardiovascular diseases later in life.

Published
2012
Full Text
View/download PDF

26. Erratum à « Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique » [Rev. Mal. Respir. 30 (10) 879–902]

Author

Cottin, V., primary, Crestani, B., additional, Valeyre, D., additional, Wallaert, B., additional, Cadranel, J., additional, Dalphin, J.-C., additional, Delaval, P., additional, Israel-Biet, D., additional, Kessler, R., additional, Reynaud-Gaubert, M., additional, Cordier, J.-F., additional, Aguilaniu, B., additional, Bouquillon, B., additional, Carré, P., additional, Danel, C., additional, Faivre, J.-B., additional, Ferretti, G., additional, Just, N., additional, Kouzan, S., additional, Lebargy, F., additional, Marchand Adam, S., additional, Philippe, B., additional, Prévot, G., additional, Stach, B., additional, and Thivolet-Béjui, F., additional

Published
2014
Full Text
View/download PDF

27. Le dépistage individuel du cancer broncho-pulmonaire en pratique. Perspectives sur les propositions du groupe de travail pluridisciplinaire de l’Intergroupe francophone de cancérologie thoracique, de la Société d’imagerie thoracique et du Groupe d’oncologie de langue française

Author

Girard, N., primary, Gounant, V., additional, Mennecier, B., additional, Greillier, L., additional, Cortot, A.B., additional, Couraud, S., additional, Besse, B., additional, Brouchet, L., additional, Castelnau, O., additional, Ferretti, G.R., additional, Frappé, P., additional, Khalil, A., additional, Lefebure, P., additional, Laurent, F., additional, Liebart, S., additional, Margery, J., additional, Molinier, O., additional, Quoix, E., additional, Revel, M.-P., additional, Stach, B., additional, Souquet, P.-J., additional, Thomas, P., additional, Trédaniel, J., additional, Lemarié, E., additional, Zalcman, G., additional, Barlési, F., additional, and Milleron, B., additional

Published
2014
Full Text
View/download PDF

29. No cross-sectional and longitudinal association of ferritin and symptoms of attention-deficit-/hyperactivity disorder in a large population-based sample of children: results from the GINIplus and LISAplus studies

Author

Romanos, M., Tiesler, C.M.T., Koletzko, S., Berdel, D., von Berg, A., Hoffmann, B., Schaaf, B., Herbarth, O., Lehmann, Irina, Bauer, C.-P., Stach, B., Gerlach, M., Schulte-Körne, G., Heinrich, J., Romanos, M., Tiesler, C.M.T., Koletzko, S., Berdel, D., von Berg, A., Hoffmann, B., Schaaf, B., Herbarth, O., Lehmann, Irina, Bauer, C.-P., Stach, B., Gerlach, M., Schulte-Körne, G., and Heinrich, J.

Abstract

Attention-deficit/hyperactivity disorder (ADHD) has been associated with alterations in iron metabolism, and low ferritin concentrations in peripheral blood have inconsistently been reported in clinically referred samples of children with ADHD. This study examined whether higher peripheral concentrations of ferritin, the major iron storage protein, are associated with decreased symptoms of ADHD in 2,805 children aged 10 years participating in two large population-based birth cohorts (GINIplus and LISAplus). Whether high ferritin concentrations at age 4 months predict lower ADHD symptoms at age 10 years was also investigated using a longitudinal approach in a subsample of 193 children. No indications for an association between peripheral ferritin concentrations and ADHD symptoms were found in this large population-based study. Re-evaluating iron substitution as a therapeutic measure for ADHD may be warranted.

Published
2013

30. Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique. Élaborées par le centre national de référence et les centres de compétence pour les maladies pulmonaires rares sous l’égide de la Société de pneumologie de langue française

Author

Cottin, V., primary, Crestani, B., additional, Valeyre, D., additional, Wallaert, B., additional, Cadranel, J., additional, Dalphin, J.C., additional, Delaval, P., additional, Israel-Biet, D., additional, Kessler, R., additional, Reynaud-Gaubert, M., additional, Cordier, J.F., additional, Aguilaniu, B., additional, Bouquillon, B., additional, Carré, P., additional, Danel, C., additional, Faivre, J.-B., additional, Ferreti, G., additional, Just, N., additional, Kouzan, S., additional, Lebargy, F., additional, Marchand Adam, S., additional, Philippe, B., additional, Prévot, G., additional, Stach, B., additional, and Thivolet-Béjui, F., additional

Published
2013
Full Text
View/download PDF

33. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: I. Early stages.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

34. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: III. Metastatic disease.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

35. Traitement des cancers bronchiques non à petites cellules et résécables. Recommandations de pratique clinique de l'European Lung Cancer Working Party

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2006

36. European Lung Cancer Working Party Clinical Practice Guidelines. Non-small cell lung cancer: II. Unresectable non-metastatic stages.

Author

Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, Wackenier, Peggy, Alexopoulos, Constantinos, Berghmans, Thierry, Berchier, M.C., Colinet, Benoît, Dequanter, Didier, Efremidis, Anna, Florin, M.C., Giner, Vicente, Jouveshomme, Stéphane, Koumakis, George, Lafitte, Jean-Jacques, Lecomte, J., Lemaitre, Jean, Louviaux, I., Mascaux, Céline, Meert, Anne-Pascale, Ninane, Vincent, Richez, Michel, Sculier, Jean-Paul, Stach, B., Vaslamatzis, Michael, and Wackenier, Peggy

Abstract

info:eu-repo/semantics/published

Published
2006

37. Hearing aids. II. Implantable hearing aids

Author

A J Gulya and Stach B

Subjects
medicine.medical_specialty, Cosmetic appearance, Tympanic Membrane, business.industry, Earmold, Temporal Bone, General Medicine, Prostheses and Implants, Audiology, medicine.disease, Ossicular Prosthesis, Hearing Aids, Treatment Outcome, Otorhinolaryngology, Acquired immunodeficiency syndrome (AIDS), otorhinolaryngologic diseases, medicine, Humans, Surgery, Aural atresia, business, Bone Conduction
Abstract

Technological advances and functional and cosmetic improvements in conventional hearing aids notwithstanding, there are still individuals for whom alternative amplification schemes are desirable. Patients generally fitted with bone-conduction hearing aids, eg, those with irreparable aural atresia, unremitting otorrhea, earmold allergy, or conductive losses not amenable to surgery, have difficulty with the pressure, poor fidelity, and unattractive appearance of these devices. Patients capable of wearing conventional air-conduction hearing aids contend with sound distortion, feedback, canal occlusion, tight earmolds, and poor cosmetic appearance. 1 A number of implantable hearing devices are in varying stages of development in an effort to overcome some of the limitations associated with conventional hearing aids.

Published
1996

38. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

Author

Berghmans, Thierry, Lafitte, Jean-Jacques, Paesmans, Marianne, Stach, B., Berchier, M.C., Wackenier, Peggy, Lecomte, J., Collon, Thierry, Mommen, Paul, Sculier, Jean-Paul, Berghmans, Thierry, Lafitte, Jean-Jacques, Paesmans, Marianne, Stach, B., Berchier, M.C., Wackenier, Peggy, Lecomte, J., Collon, Thierry, Mommen, Paul, and Sculier, Jean-Paul

Abstract

Few chemotherapeutic agents have demonstrated their efficacy in malignant mesothelioma. The cisplatin plus doxorubicin combination has one of the highest response rates. Epirubicin is an anthracyclin, analogous to doxorubicin, with a different toxicologic pattern. As there are no data on the activity of the combination cisplatin plus epirubicin in malignant mesothelioma, the European Lung Cancer Working Party (ELCWP) designed a phase II study with response rate as primary objective. Sixty-nine eligible patients with malignant pleural mesothelioma were centrally registered. The majority of the patients were male (n = 59), had a Karnofsky performance status of 80 or more (n = 62) and presented with an epithelial histologic subtype (n = 43). Median age was 62 years. In nine patients, metastases were documented at the initial work-up, mainly in bone, lung and skin. Three hundred and twenty-four cycles of chemotherapy were administered. The main toxicities were nausea and vomiting, neutropenia and alopecia. Among 63 assessable patients, response rate was 19.0% (95% confidence interval [CI] 9-29%). Median survival was 13.3 months. In multivariate analysis, poor prognostic factors for survival were neutrophil count and CALGB groups 4-6. In conclusion, cisplatin plus epirubicin appears as an effective regimen in malignant mesothelioma, with a favourable toxicity profile. However, it does not demonstrate superior activity to other active regimens in this disease. © 2005 Elsevier Ireland Ltd. All rights reserved., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2005

40. A phase II study of cisplatin (CDDP) and epirubicin (EPI) in malignant pleural mesothelioma (MPM)

Author

Berghmans, Thierry, Lafitte, Jean-Jacques, Stach, B., Recloux, P, Lecomte, J., Collon, C., Ninane, V, Klastersky, Jean, Sculier, Jean-Paul, Berghmans, Thierry, Lafitte, Jean-Jacques, Stach, B., Recloux, P, Lecomte, J., Collon, C., Ninane, V, Klastersky, Jean, and Sculier, Jean-Paul

Abstract

ECCO 12, Copenhagen, 21-25/09/03 A study by the European Lung Cancer Working Party (ELCWP)., info:eu-repo/semantics/published, suppl.5

Published
2003

43. Éditorial

Author

Carré, Ph., primary, Stach, B., additional, and Charpin, D., additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results